FDA approves Darzalex Faspro for high-risk smoldering multiple myeloma

The U.S. Food and Drug Administration has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) as a single-agent ...
The American Journal of Managed Care

FDA Approves Ziftomenib for R/R NPM1-Mutated AML

Ziftomenib (Komzifti; Kura Oncology and Kyowa Kirin), an oral, once-daily, selective menin inhibitor, has received approval from the FDA for the treatment of adult patients with relapsed or refractory ...
CURE

FDA Approves Komzifti for NPM1-Mutant Acute Myeloid Leukemia

The U.S. Food and Drug Administration (FDA) has approved Komzifti (ziftomenib), which is a type of treatment known as a menin ...

US FDA approves Kura-Kyowa's blood cancer therapy

The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, ...

Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refract…

NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients –– Acute unmet need in R/R ...

Kura Oncology wins FDA approval for leukemia drug

The U.S. Food and Drug Administration on Thursday approved ziftomenib (Komzifti), a leukemia drug developed by Kura Oncology ...